Quantifying Plasma Levels of Transforming Growth Factor β1 in Idiopathic Pulmonary Fibrosis

Molina-Molina, María; Lario, Sergio; Luburich, Patricio; Ramírez, José; Carrión, María Teresa; Xaubet, Antoni

doi:10.1016/S1579-2129(06)60550-8

Archivos de Bronconeumología

ISSN: 0300-2896

Archivos de Bronconeumologia is an international journal that publishes original studies whose content is based upon results of research initiatives dealing with several aspects of respiratory medicine including epidemiology, respiratory physiology, pathophysiology of respiratory diseases, clinical management, thoracic surgery, pediatric lung diseases, respiratory critical care, respiratory allergy and translational research. Other types of articles such as editorials, reviews, and different types of letters are also published in the journal. Additionally, the journal expresses the voice of the following scientific societies: the Spanish Respiratory Society of Pneumology and Thoracic Surgery (SEPAR; https://www.separ.es/), the Latin American Thoracic Society (ALAT; https://alatorax.org/), and the Iberian American Association of Thoracic Surgery (AIACT; http://www.aiatorax.com/).

It is a monthly journal in which all manuscripts are sent to peer-review and handled by the editor or an associate editor from the team and the final decision is made on the basis of the comments from the expert reviewers and the editors. The journal is published solely in English. All the published data is composed of novel manuscripts not previously published in any other journal and not being in consideration for publication in any other journal..

The journal is indexed at Science Citation Index Expanded, Medline/Pubmed, Embase and SCOPUS. Access to any published article is possible through the journal's web page as well as from Pubmed, ScienceDirect, and other international databases. Furthermore, the journal is also present in X, Facebook and Linkedin. Manuscripts can be submitted electronically using the following web site: https://www.editorialmanager.com/ARBR/.

Indexed in:

Current Contents/Clinical Medicine, JCR SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, SCOPUS, IBECS

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

8.7

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

3.5

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.464

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.482

View more metrics

Open Access Option

Journal Information

Previous article | Next article

Vol. 42. Issue 8.

Pages 380-383 (August 2006)

More article options

Pages 380-383 (August 2006)

Original Articles

DOI: 10.1016/S1579-2129(06)60550-8

Full text access

Quantifying Plasma Levels of Transforming Growth Factor β1 in Idiopathic Pulmonary Fibrosis

Visits

4843

Download PDF

María Molina-Molinaa,

Corresponding author

mariamolinamolina@hotmail.com

Correspondence: Dra. M. Molina-Molina. Servicio de Neumología. Hospital Clínic. Villarroel, 170. 08036 Barcelona. España

, Sergio Lariob, Patricio Luburichc, José Ramírezd, María Teresa Carrióna, Antoni Xaubeta

a Sectión de Neumología, Hospital Clinic, IDIBAPS, Universidad de Barcelona, Barcelona, Spain

b Unidad de Trasplante Renal, Hospital Clinic, IDIBAPS, Universidad de Barcelona, Barcelona, Spain

c Servicio de Radiodiagnóstico, Hospital Clínic, IDIBAPS, Universidad de Barcelona, Barcelona, Spain

d Servicio de Anatomía Patológica, Hospital Clínic, IDIBAPS, Universidad de Barcelona, Barcelona, Spain

This item has received

4843 Visits

Article information

Statistics

Objective

Transforming growth factor β1 (TGF-β1) is one of the key profibrotic mediators in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The purpose of this study was to investigate the prognostic value of quantifying TGF-β1 levels in patients with IPF.

Patients and methods

We conducted a prospective study of 29 IPF patients and 27 healthy controls. Enzyme-linked immunosorbent assays were used to quantify TGF-β1 levels.

Results

Mean (SD) TGF-β1 levels were significantly higher in the IPF patients than in the control subjects (11.1 [7.5] ng/mL vs 4 [2.4] ng/mL; P<.01). Weak inverse correlations were observed between TGF-β1 levels and both forced vital capacity and total lung capacity. Thirteen IPF patients were evaluated at 8 (1.2) months (range, 5–9 months). The mean TGF-β1 level was 18.2 (15) ng/mL and there were no significant differences with respect to the initial measurement of 11.1 (7.5) ng/mL.

No correlation was observed between changes in respiratory function and changes in TGF-β1 levels.

Conclusions

Although plasma levels of TGF-β1 were high in the patients with IPF, they do not appear to be a useful prognostic marker of disease activity or therapeutic response.

Key words:

Idiopathic pulmonary fibrosis

Interstitial pulmonary diseases

Transforming growth factor β1

Serum markers

Objetivo

El factor transformador del crecimiento β1 (TGF-β1) es uno de los mediadores fibrogénicos con más relevancia en la patogenia de la fibrosis pulmonar idiopática (FPI). El objetivo del estudio ha sido investigar el valor pronóstico de la determinación en plasma del TGF-β1 en la FPI.

Pacientes y métodos

Se ha realizado un estudio prospective en el que se incluyó a 29 pacientes con FPI y 27 controles sanos. La determinación del TGF-β1 se realizó mediante enzimoinmunoanálisis.

Resultados

La concentración de TGF-β1 de significativamente mayor en los pacientes con FPI que en los controles (media ± desviación estándar: 11,1 ± 7,5 frente a 4 ± 2,4 ng/ml; p < 0,01). Se observó una débil relación inversa de la concentración del TGF-β1 con los valores de la capacidad vital forzada y de la capacidad pulmonar total. Se evaluó a 13 pacientes con FPI a los 8 ± 1,2 meses (rango: 5–9 meses). La concentración de TGF-β1 fue de 18,2 ± 15 ng/ml, sin diferencias significativas respecto a la primera determinación (11,1 ± 7,5 ng/ml). No se observó ninguna relación entre los cambios evolutivos en la exploración funcional respiratoria y los cambios en la concentración de TGF-β1.

Conclusiones

Aunque la concentración plasmática de TGF-β1 está elevada en los pacientes con FPI, este parámetro no parece ser útil como marcador del pronóstico de la enfermedad ni de la respuesta terapéutica.

Palabras clave:

Fibrosis pulmonar idiopática

Enfermedades pulmonares intersticiales

Factor transformador del crecimiento β1

Marcadores séricos

Full text is only aviable in PDF

References

[1]

TE King, M Schwarz, K Brown, J Ose, T Coolí, J Waldron, et al.

Idiopathic pulmonary fibrosis. Relationship between histopathologic features and mortality.

Am J Respir Crit Care Med, 164 (2001), pp. 1025-1032

http://dx.doi.org/10.1164/ajrccm.164.6.2001056 | Medline

[2]

PW Noble, RJ Homer.

Idiopathic pulmonary fibrosis: new insights into pathogenesis.

Clin Chest Med, 25 (2004), pp. 749-758

http://dx.doi.org/10.1016/j.ccm.2004.04.003 | Medline

[3]

JM Fellrath, RM du Bois.

Idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis.

Clin Exp Med, 3 (2003), pp. 65-83

http://dx.doi.org/10.1007/s10238-003-0010-3 | Medline

[4]

A Pardo, M Selman.

Idiopathic pulmonary fibrosis: new insights in its pathogenesis.

Int J Biochem Cell Biol, 34 (2002), pp. 1534-1538

Medline

[5]

ES White, MH Lazar, VJ Thannickal.

Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis.

J Pathol, 201 (2003), pp. 343-354

http://dx.doi.org/10.1002/path.1446 | Medline

[6]

C Ramos, M Montano, J García-Álvarez, V Ruiz, BD Uhal, M Selman, et al.

Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression.

Am J Respir Cell Mol Biol, 24 (2001), pp. 591-598

http://dx.doi.org/10.1165/ajrcmb.24.5.4333 | Medline

[7]

U Bartram, CP Speer.

The role of transforming growth factor beta in lung development and disease.

Chest, 125 (2004), pp. 754-765

Medline

[8]

TJ Broekelmann, AH Limper, TV Colby, JA McDonald.

Transforming growth factor beta-1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis.

Proc Natl Acad Sci U S A, 88 (1991), pp. 6642-6646

Medline

[9]

N Khalil, TV Parek, R O'Connor, N Antman, W Kepron, T Yehaulaeshet, et al.

Regulation of the effects of TGF-β1 by activation of latent TGF-β1 and differential expression of TGF-β1 receptors (TβR-I and Tβ-II) in idiopathic pulmonary fibrosis.

Thorax, 56 (2001), pp. 907-915

Medline

[10]

G Westergren-Thorsson, J Hernnas, B Sarnstrand, A Oldberg, D Heinegard, A Malmastrom.

Altered expression of small proteoglycans, collagen, and transforming growth factor-β1 in developing bleomycin-induced pulmonary fibrosis in rats.

J Clin Invest, 92 (1993), pp. 632-637

http://dx.doi.org/10.1172/JCI116631 | Medline

[11]

YD Xu, J Hua, A Mui, R O'Connor, G Grotendorst, N Khalil.

Release of biologically active TGF-beta1 by alveolar epithelial cells results in pulmonary fibrosis.

Am J Physiol Lung Cell Mol Physiol, 285 (2003), pp. L522-L526

http://dx.doi.org/10.1152/ajplung.00110.2003 | Medline

[12]

American Thoracic Society.

Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Am J Respir Crit Care Med, 161 (2000), pp. 646-664

http://dx.doi.org/10.1164/ajrccm.161.2.ats3-00 | Medline

[13]

A Xaubet, J Ancochea, R Blanquer, C Montero, F Morell, E Rodríguez, et al.

Diagnóstico y tratamiento de las enfermedades pulmonares intersticiales difusas.

Arch Bronconeumol, 39 (2003), pp. 580-600

Medline

[14]

SJ Yong, A Adlakha, AH Limper.

Circulating transforming growth factor-β1: a potential marker of disease activity during idiopathic pulmonary fibrosis.

Chest, 120 (2001), pp. 68S-70S

Medline

[15]

K Greene, TE King, Y Kuroki, B Bucher-Bartelson, GW Hunninghake, LS Newman, et al.

Serum surfactant proteins-A and D as biomarkers in idiopathic pulmonary fibrosis.

Eur Respir J, 19 (2002), pp. 439-446

Medline

[16]

H Ohnishi, A Yokoyama, K Kondo, H Hamada, M Abe, K Nishimura, et al.

Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases.

Am J Respir Crit Care Med, 165 (2002), pp. 378-381

http://dx.doi.org/10.1164/ajrccm.165.3.2107134 | Medline

[17]

N Takahashi, T Fujishima, H Koba, S Murakami, K Kurokawa, Y Shibuya, et al.

Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent.

Am J Respir Crit Care Med, 162 (2000), pp. 1109-1114

http://dx.doi.org/10.1164/ajrccm.162.3.9910080 | Medline

[18]

SP Matusiewicz, IJ Williamson, PJ Sime, PH Brown, PR Wenham, GK Crompton, et al.

Plasma lactate dehydrogenase: a marker of disease activity in cryptogenic fibrosing alveolitis and extrinsic allergic alveolitis.

Eur Respir J, 6 (1993), pp. 1282-1286

Article | Medline

[19]

MW Ziegenhagen, P Zabel, G Zissel, M Schlaak, J Müller-Quernheim.

Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity.

Am J Respir Crit Care Med, 157 (1998), pp. 762-768

http://dx.doi.org/10.1164/ajrccm.157.3.9705014 | Medline

[20]

A Yokohama, N Kohno, H Hamada, M Sakatani, E Ueda, K Kondo, et al.

Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis.

Am J Respir Crit Care Med, 158 (1998), pp. 1680-1684

http://dx.doi.org/10.1164/ajrccm.158.5.9803115 | Medline

[21]

S Hayashi, K Abe, H Matsuoka, S Goya, H Morishita, M Mori, et al.

Increased level of soluble E-selectin in the serum from patients with idiopathic pulmonary fibrosis.

Inflammation, 28 (2004), pp. 1-5

Medline

[22]

K Kuwano, T Maeyama, I Inoshima, K Ninomiya, N Hagimoto, M Yoshimi, et al.

Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.

Respirology, 7 (2002), pp. 15-21

Medline

[23]

J Ancochea, E Antón, A Casanova.

Nuevas estrategias terapéuticas en la fibrosis pulmonar idiopätica.

Arch Bronconeumol, 40 (2004), pp. 16-22

Medline

[24]

F Salez, P Gosset, MC Copin, CL Degros, AB Tonnel, B Wallaert.

Transforming growth factor-β1 in sarcoidosis.

Eur Respir J, 12 (1998), pp. 913-999

Medline

[25]

MR Awad, A El-Gamel, P Hasleton, DM Turner, PJ Sinnot, IV Hutchinson.

Genotype variation in the transforming growth factor β1 gene.

Transplantation, 66 (1998), pp. 1014-1020

Medline

[26]

A el-Gamel, M Awad, E Sim, P Haselton, N Yonan, J Egan, et al.

Transforming growth factor-β1 and lung allograft.

Eur J Cardiothoracic Surg, 13 (1998), pp. 424-430

[27]

A el-Gamel, M Awad, P Haselton, NA Yonan, JA Hutchinson, CS Campbell, et al.

Transforming growth factor-β genotype and lung allograft fibrosis.

J. Heart Lung Transplant, 18 (1999), pp. 517-523

Medline

[28]

A Xaubet, S Marín-Arguedas, S Lario, J Ancochea, F Morell, J Ruiz-Manzano, et al.

TGF beta-1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis.

Am J Respir Crit Care Med, 168 (2003), pp. 431-435

http://dx.doi.org/10.1164/rccm.200210-1165OC | Medline

[29]

MS Anscher, WP Peters, H Reisenbichler, W Petros, RL Jirtle.

Transforming growth factor-β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer.

N Engl J Med, 328 (1993), pp. 1592-1598

http://dx.doi.org/10.1056/NEJM199306033282203 | Medline

This study was funded by grants from SEPAR: Fundación Respira 2000, FIS 00/371, and Red Respira V-2003-REDC 11 D-O.

Tools

Indexed in:

Follow us:

Subscribe:

Subscribe to our newsletter